These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 11687017)
81. On alcohol availability and cirrhosis mortality. Douglass RL Am J Public Health; 1982 Apr; 72(4):403-4. PubMed ID: 7065324 [No Abstract] [Full Text] [Related]
82. Unlocking Colchicine's Untapped Potential: A Paradigm Shift in Hepatocellular Carcinoma Prevention. Lin JJ; Lin CL; Chen CC; Lin YH; Cho DY; Chen X; Chen DC; Chen HY Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894398 [No Abstract] [Full Text] [Related]
83. [Challenges and optimization strategies for clinical research and the development of new drugs for liver fibrosis]. Cai XB; Qu Y; Lu LG Zhonghua Gan Zang Bing Za Zhi; 2024 Apr; 32(4):303-305. PubMed ID: 38733183 [TBL] [Abstract][Full Text] [Related]
84. [Trial to treat alcoholic cirrhosis with ascites infusions]. GIRARD M; FOURNET Lyon Med; 1949 Apr; 181(17):257-63. PubMed ID: 18129908 [No Abstract] [Full Text] [Related]
85. [Trial to treat alcoholic cirrhosis with ascites infusions]. GIRARD M; MIGUET ; MARTIN G J Med Lyon; 1949 Apr; 30(702):269-76. PubMed ID: 18117992 [No Abstract] [Full Text] [Related]
86. Some epidemiological aspects of cirrhosis of the liver; a study of mortality statistics. LILIENFELD AM; KORNS RF Am J Hyg; 1950 Jul; 52(1):65-81. PubMed ID: 15432442 [No Abstract] [Full Text] [Related]
87. Significance of clinical findings in cirrhosis of the liver; a study of 93 autopsied cases. HOFFMAN J; LISA JR Am J Med Sci; 1947 Nov; 214(5):525-8. PubMed ID: 20271024 [No Abstract] [Full Text] [Related]
89. Research in brief: Colchicine for chronic coronary disease: a recent randomised controlled trial. Pooni RS; Ismail TF Clin Med (Lond); 2021 Jan; 21(1):e1. PubMed ID: 33479074 [No Abstract] [Full Text] [Related]
90. Inhibition of quartz-induced fibrosis of the liver by aluminum. HARRISON CV; WRIGHT BM; KING EJ J Pathol Bacteriol; 1950 Jul; 62(3):443-4. PubMed ID: 14784909 [No Abstract] [Full Text] [Related]
91. Too Stiff, Too Late . . . Timing Is Everything in Antiangiogenic Treatment of Liver Fibrosis. Greuter T; Shah VH Hepatology; 2019 Jan; 69(1):449-451. PubMed ID: 30070720 [No Abstract] [Full Text] [Related]
92. Colchicine and clinical trials for hand osteoarthritis. Plotz B; Pillinger M; Samuels J Osteoarthritis Cartilage; 2022 Jan; 30(1):172-173. PubMed ID: 33636316 [No Abstract] [Full Text] [Related]
93. FAP: Not Just a Biomarker but Druggable Target in Liver Fibrosis. Kim J; Seki E Cell Mol Gastroenterol Hepatol; 2023; 15(4):1018-1019. PubMed ID: 36681094 [No Abstract] [Full Text] [Related]
94. Clues to cirrhosis - a focus on fibrosis. Ray K Nat Rev Gastroenterol Hepatol; 2019 Dec; 16(12):705. PubMed ID: 31649342 [No Abstract] [Full Text] [Related]
95. Corrigendum to: Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomised trials. Eur Heart J; 2021 Aug; 42(33):3202. PubMed ID: 34023880 [No Abstract] [Full Text] [Related]
96. A new model for estimation of significant fibrosis in primary care. SAFE to use? Hagström H Hepatology; 2023 Jan; 77(1):18-19. PubMed ID: 35491438 [No Abstract] [Full Text] [Related]